Encompass Health (NYSE: EHC) director adds shares via awards and deferrals

Rhea-AI Filing Summary

Encompass Health director Christopher R. Reidy acquired equity through routine compensation-related awards. On July 16, 2026 he received 319 restricted stock units tied to a $0.19 dividend and a $109.88 closing price, and on July 15, 2026 he acquired 21 shares via the Directors Deferred Stock Investment Plan, bringing his direct holdings to 17,777 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Reidy Christopher R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Encompass Health Common Stock	319	$112.40	$36K
Grant/Award	Encompass Health Common Stock	21	$0.00	--

Holdings After Transaction: Encompass Health Common Stock — 17,777 shares (Direct)

Footnotes (1)

1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on July 15, 2026.

Key Figures

RSUs credited: 319 shares Plan shares acquired: 21 shares Dividend per share: $0.19 +2 more

5 metrics

RSUs credited 319 shares Restricted stock units credited on July 16, 2026 tied to a dividend payment

Plan shares acquired 21 shares Shares purchased under the Directors Deferred Stock Investment Plan on July 15, 2026

Dividend per share $0.19 Dividend on Encompass Health common stock paid July 15, 2026 used in RSU calculation

Closing price used $109.88 Closing price on July 15, 2026 applied to compute RSUs from the cash dividend

Shares held after transactions 17,777 shares Direct holdings of Encompass Health common stock following July 2026 director awards

Key Terms

restricted stock units, non-qualified deferral plan, Directors Deferred Stock Investment Plan, dividends that are reinvested

4 terms

restricted stock units financial

"additional restricted stock units ("RSUs") are credited to each non-employee director's account"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

non-qualified deferral plan financial

"Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan"

Directors Deferred Stock Investment Plan financial

"The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan"

dividends that are reinvested financial

"cash dividends that are reinvested by the Plan administrator in the Company's common stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 04:24 PM Accepted by SEC EDGAR 07/16/2026 - 04:23 PM Learn about SEC filing dates

FAQ

What insider transactions did Encompass Health (EHC) director Christopher R. Reidy report?

Christopher R. Reidy reported acquiring 319 restricted stock units on July 16, 2026 and 21 shares on July 15, 2026. Both arose under director compensation and fee-deferral arrangements, increasing his direct holdings to 17,777 Encompass Health common shares.

How many Encompass Health (EHC) shares does Christopher R. Reidy hold after these transactions?

After the reported transactions, Christopher R. Reidy directly holds 17,777 shares of Encompass Health common stock. This figure reflects the addition of 319 restricted stock units and 21 shares credited in mid-July 2026 under the company’s director programs.

What is the Directors Deferred Stock Investment Plan mentioned for Encompass Health (EHC)?

The Directors Deferred Stock Investment Plan is a non-qualified deferral plan allowing non-employee directors to defer portions of 2026 fees. Deferred fees are used each quarter to buy Encompass Health common stock, with cash dividends reinvested in additional shares for participating directors.

How were the 319 restricted stock units for Encompass Health (EHC) calculated?

The 319 restricted stock units were credited based on outstanding RSUs, a $0.19 per-share dividend paid July 15, 2026, and the $109.88 closing price that day. The formula multiplies existing RSUs by the dividend and divides by the closing price.

Were any derivatives involved in Christopher R. Reidy’s Encompass Health (EHC) Form 4 transactions?

The reported transactions both involve Encompass Health common stock, not options or other derivative securities. The accompanying data and footnotes list only restricted stock units and shares acquired through dividend credits and a director fee deferral plan for these dates.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reidy Christopher R

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM ALABAMA 35242

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	07/15/2026		A		21(1)	A	$0	17,458	D
Encompass Health Common Stock	07/16/2026		A		319(2)	A	$112.4	17,777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $109.88. The transaction reported on this Form 4 is an award of RSUs as sociated with that dividend payment.

2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the director's fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on July 15, 2026.

	/s/ Patrick Darby, attorney-in-fact for Christopher R. Reidy	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)